Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

Seminars in Oncology
Joseph ObeidCraig L Slingluff

Abstract

Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies, there is renewed enthusiasm for optimizing cancer vaccines for use to prevent recurrence in early-stage cancers and/or to combine with other immune therapies for therapy of advanced cancers. Future advancements in vaccine therapy will involve the identification and selection of effective antigen formulations, optimization of adjuvants, dendritic cell (DC) activation, and combination therapies. In this summary we present the current practice, the broad collection of challenges, and the promising future directions of vaccine therapy for cancer.

References

Sep 25, 1999·International Journal of Cancer. Journal International Du Cancer·L H BrinckerhoffC L Slingluff
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vernon K SondakLawrence E Flaherty
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey A SosmanUNKNOWN Southwest Oncology Group
Oct 14, 2003·Drug Discovery Today·Dante J Marciani
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffPatrice K Rehm
Apr 18, 2008·Nature Reviews. Cancer·Cornelis J M Melief, Sjoerd H van der Burg
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig L SlingluffPatrice K Rehm
Dec 9, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Blaise ClarkeC Blake Gilks
Jul 8, 2009·Proceedings of the National Academy of Sciences of the United States of America·Florence R DepontieuSuzanne L Topalian
Nov 6, 2009·The New England Journal of Medicine·Gemma G KenterCornelis J M Melief
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark B FariesDonald L Morton
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffKimberly A Chianese-Bullock
Apr 28, 2010·Expert Opinion on Biological Therapy·Morten Frier GjerstorffHenrik Jorn Ditzel
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Aug 24, 2010·Journal of Translational Medicine·Jochen T SchaeferCraig L Slingluff
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul F RobbinsSteven A Rosenberg
Jun 3, 2011·The New England Journal of Medicine·Douglas J SchwartzentruberPatrick Hwu
Oct 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R WeissEna Wang
Apr 25, 2012·Cancer Immunology, Immunotherapy : CII·Kelly Barrios, Esteban Celis
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul SabbatiniSacha Gnjatic
Feb 5, 2013·Journal of Immunotherapy·Richard A MorganSteven A Rosenberg
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
May 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffJohn M Kirkwood
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fernando Ulloa-MontoyaVincent G Brichard

❮ Previous
Next ❯

Citations

Dec 26, 2015·Molecular Pharmaceutics·Ásdís HjálmsdóttirPål Johansen
Mar 13, 2016·Seminars in Oncology·Malgorzata E WojtowiczAsad Umar
Apr 15, 2016·Science Translational Medicine·Pedro RomeroGeorge Coukos
Jul 12, 2016·Cancers·Ida SilvestriAlessandro Sciarra
Dec 28, 2016·Cell Research·Rachel L SabadoNina Bhardwaj
Mar 17, 2016·Oncotarget·Dino KocijancicSiegfried Weiss
Apr 13, 2018·Cancer Immunology, Immunotherapy : CII·Cécile Gouttefangeas, Hans-Georg Rammensee
Dec 1, 2016·Melanoma Management·Robert O DillmanAndrew N Cornforth
Aug 12, 2018·Vaccines·Angelika Terbuch, Juanita Lopez
Jan 9, 2019·Frontiers in Immunology·Nataschja I HoGosse J Adema
Jun 21, 2020·Cancer Immunology, Immunotherapy : CII·Stefania CuzzubboAntoine F Carpentier
Aug 9, 2020·Nature Reviews. Drug Discovery·Alexandre HarariLana E Kandalaft
Dec 14, 2018·Oncoimmunology·Lucillia BezuLorenzo Galluzzi
Nov 17, 2020·Frontiers in Immunology·Adarsh KumbhariPeter S Kim
Mar 9, 2021·Frontiers in Immunology·Stefania CuzzubboStephanie E B McArdle
Jul 28, 2019·Journal of Cellular Physiology·Fatemeh RafieeniaSeyed Hamid Aghaee-Bakhtiari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.